Ken Griffin
RPRX icon

Ken Griffin’s Royalty Pharma RPRX Stock Holding History

Ken Griffin’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129M Sell
2,681,069
-2,592,796
-49% -$114M 0.02% 661
2025
Q4 		$204M Buy
5,273,865
+4,879,192
+1,236% +$186M 0.03% 480
2025
Q3 		$13.9M Sell
394,673
-132,615
-25% -$4.8M ﹤0.01% 2777
2025
Q2 		$19M Sell
527,288
-1,538,488
-74% -$51M ﹤0.01% 2208
2025
Q1 		$64.3M Sell
2,065,776
-832,188
-29% -$26.4M 0.01% 963
2024
Q4 		$73.9M Buy
+2,897,964
New +$76.8M 0.01% 951
2024
Q2 		– Sell
-97,919
Closed -$2.71M – 15228
2024
Q1 		$2.97M Sell
97,919
-389,101
-80% -$11.5M ﹤0.01% 4807
2023
Q4 		$13.7M Buy
487,020
+363,939
+296% +$10M ﹤0.01% 2448
2023
Q3 		$3.34M Sell
123,081
-532,291
-81% -$15.8M ﹤0.01% 4297
2023
Q2 		$20.1M Sell
655,372
-423,582
-39% -$14.3M ﹤0.01% 1877
2023
Q1 		$38.9M Buy
1,078,954
+567,014
+111% +$21M 0.01% 1302
2022
Q4 		$20.2M Buy
511,940
+175,979
+52% +$7.35M ﹤0.01% 1952
2022
Q3 		$13.5M Buy
335,961
+76,116
+29% +$3.25M ﹤0.01% 2355
2022
Q2 		$10.9M Sell
259,845
-1,323,288
-84% -$54.2M ﹤0.01% 2572
2022
Q1 		$61.7M Buy
1,583,133
+1,371,252
+647% +$53.8M 0.01% 969
2021
Q4 		$8.44M Buy
211,881
+99,702
+89% +$3.87M ﹤0.01% 3351
2021
Q3 		$4.05M Sell
112,179
-377,172
-77% -$14.7M ﹤0.01% 4718
2021
Q2 		$20.1M Buy
489,351
+351,746
+256% +$15M ﹤0.01% 2081
2021
Q1 		$6M Sell
137,605
-186,636
-58% -$8.85M ﹤0.01% 3867
2020
Q4 		$16.2M Buy
324,241
+256,692
+380% +$10.9M ﹤0.01% 2037
2020
Q3 		$2.84M Sell
67,549
-856,056
-93% -$36.7M ﹤0.01% 4075
2020
Q2 		$44.8M Buy
+923,605
New +$45.7M 0.02% 869

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ken Griffin's RPRX Position: Q1 2026 in Review

Ken Griffin reduced its Royalty Pharma (RPRX) stake by 49% in Q1 2026, selling an estimated $114M and leaving 2,681,069 shares worth $129M. The position accounts for 0.02% of the portfolio, ranked #661.

Ken Griffin first reported a position in RPRX in Q2 2020 and has held it in 22 quarters since. The position peaked at $204M in Q4 2025. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Ken Griffin held 2,681,069 shares of Royalty Pharma worth $129M as of Q1 2026.
  • Ken Griffin sold 2,592,796 Royalty Pharma shares in Q1 2026, an estimated $114M.
  • Royalty Pharma made up 0.02% of Ken Griffin's portfolio in Q1 2026, its #661 holding.
  • Ken Griffin first reported a position in Royalty Pharma in Q2 2020 and has held it in 22 quarters since.
  • Ken Griffin's Royalty Pharma position peaked at $204M in Q4 2025.
  • 590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.